Doctors Revision

Systemic fungal infections

Text size
On this page

Overview

Systemic (deep or invasive) fungal infections occur when fungi that usually live harmlessly on body surfaces or in the environment invade tissues and spread to organs — lung, blood, meninges, bone, eye and skin. They divide broadly into opportunistic mycoses (candidiasis, aspergillosis, cryptococcosis) that exploit immunosuppression, and the endemic dimorphic mycoses (histoplasmosis, coccidioidomycosis, blastomycosis) that infect anyone from an environmental source. With HIV a leading driver in sub-Saharan Africa, cryptococcosis and histoplasmosis are major causes of death in advanced AIDS — yet both are diagnosable at the bedside and treatable with antifungals that every clinician should know.

A chronic “TB-like” illness that fails TB treatment — especially with meningitis, skin lesions or adrenal failure in an HIV-positive patient — should trigger fungal antigen testing before giving more antibiotics.

Learning objectives

  • List the major systemic fungi and their routes of acquisition.
  • Identify the patients at highest risk: HIV, neutropenia, steroids, transplant, diabetes.
  • Recognise the clinical syndromes: oral and oesophageal candidiasis, invasive candidiasis, aspergillosis, cryptococcal meningitis, histoplasmosis.
  • Select diagnostic tests: microscopy, culture, cryptococcal antigen, galactomannan, β-D-glucan, imaging.
  • Prescribe the main antifungals with correct dosing and safety monitoring.

Important systemic fungi

Scroll the table sideways on a smaller screen.

Important systemic fungi
FungusType / acquisitionClassic clinical picture
Candida albicans and other speciesYeast; normal flora of mouth, gut and vaginaOral and oesophageal thrush; invasive candidaemia in lines, ICU patients and neutropenia
Aspergillus fumigatusMould; inhaled spores from decaying matterInvasive pulmonary aspergillosis in neutropenia; allergic bronchopulmonary aspergillosis in asthma
Cryptococcus neoformansEncapsulated yeast; pigeon/bat droppings, soilMeningitis in advanced HIV; pulmonary and disseminated disease
Histoplasma capsulatumDimorphic; bird/bat-droppings-enriched soilPneumonia, disseminated reticuloendothelial disease with fever, weight loss, hepatosplenomegaly
Coccidioides spp.Dimorphic; desert dust (Americas)Pneumonia with erythema nodosum; meningitis in dissemination
Mucorales (mucormycosis)Mould; uncontrolled diabetes, ketoacidosis, iron overloadRhinocerebral disease with black palatal eschar — a surgical emergency

Risk factors and pathogenesis

Immunity to fungi rests on neutrophils and T-cell–mediated immunity. Defects in these defences define the at-risk population: advanced HIV (CD4 under 100–200 cells/µL), chemotherapy-induced neutropenia, high-dose or prolonged corticosteroids, transplant immunosuppression, poorly controlled diabetes, malignancy, malnutrition and critical illness with central lines and broad-spectrum antibiotics. Inhaled conidia that a healthy lung clears can germinate and invade blood vessels when defences fail — hence haemoptysis and infarcted cavitary lesions in aspergillosis, and vascular invasion with stroke in mucormycosis.

Clinical syndromes

Candidiasis

Oral thrush: removable white plaques on an erythematous base, burning and taste disturbance; a marker of immunosuppression — in an adult, always ask why (HIV, diabetes, steroids, antibiotics, chemotherapy). Oesophageal candidiasis: odynophagia and retrosternal pain with oral thrush — in AIDS it is an AIDS-defining illness. Invasive candidiasis: persistent fever despite antibiotics in a line or ICU patient, with chorioretinal or skin lesions; blood cultures are often negative.

Aspergillosis

Invasive pulmonary aspergillosis in neutropenia: fever, cough, pleuritic pain, haemoptysis; a halo sign (ground-glass around a nodule) on CT is early, and an air-crescent sign later. Allergic bronchopulmonary aspergillosis (ABPA) in asthma: wheeze, fleeting pulmonary infiltrates, brown mucus plugs, very high IgE.

Cryptococcosis

Subacute meningitis over weeks: headache, fever, neck stiffness, vomiting, confusion and cranial-nerve palsies, in a patient with advanced HIV. Raised intracranial pressure is common and dangerous. Disseminated skin lesions (umbilicated papules mimicking molluscum) point to the diagnosis.

Histoplasmosis

Acute pulmonary: fever, cough, chest pain after cave or chicken-house exposure. Disseminated: weeks of fever, weight loss, hepatosplenomegaly, anaemia, oral ulcers and adrenal failure in advanced AIDS — a classic TB mimic.

Diagnosis

Scroll the table sideways on a smaller screen.

Diagnostic tests in systemic fungal infection
TestUseCaution
India ink stain of CSFVisualise encapsulated cryptococciInsensitive (about 50%); positive in heavy loads
Cryptococcal antigen (CrAg) — serum and CSF lateral flowRapid, sensitive bedside test for cryptococcosisScreen HIV patients with CD4 under 100 even without symptoms (CRAG screening)
Fungal culture (blood, sputum, CSF, tissue)Species identification and susceptibilitySlow (days–weeks); alert laboratory — mould cultures are an aerosol hazard
Galactomannan antigen (serum/BAL)Early marker of invasive aspergillosisFalse positives with piperacillin-tazobactam and gut translocation
β-D-glucanScreen for many invasive fungal infectionsDoes not detect cryptococcus or mucormycosis; false positives with dialysis, some antibiotics
Histoplasma antigen (urine/serum)Rapid diagnosis of disseminated histoplasmosisCross-reacts with other dimorphic fungi
Histopathology of tissueSee yeast, pseudohyphae, hyphae or spherulesGuides urgent therapy (e.g., mucormycosis needs surgery plus amphotericin)

Antifungal pharmacology

Scroll the table sideways on a smaller screen.

Major systemic antifungals — doses and cautions
DrugDoseMechanism / indicationsAdverse effects, contraindications, interactions
FluconazoleOral/IV candidiasis: 100–200 mg daily × 7–14 days; oesophageal: 200–400 mg daily × 14–21 days; cryptococcal consolidation: 400 mg daily (after induction)Azole; blocks ergosterol synthesis. Thrush, oesophageal candidiasis, cryptococcosis consolidation, some histoplasmosisHepatotoxicity, QT prolongation; CYP inhibitor — raises levels of warfarin, phenytoin, some ARVs; resistance common in recurrent Candida
Amphotericin B (liposomal)3–4 mg/kg IV daily; conventional deoxycholate 0.7–1 mg/kg IV daily where liposomal unavailableBinds ergosterol → membrane pores. Severe/disseminated disease: cryptococcal and histoplasma meningitis induction, invasive aspergillosis, mucormycosisNephrotoxicity (pre-hydrate; monitor creatinine, K+, Mg2+), infusion reactions (“shake and bake”: fever, rigors — give paracetamol/pethidine and slow the infusion), anaemia. Liposomal is far better tolerated
Flucytosine (5-FC)25 mg/kg QDS orally (e.g., 100 mg/kg/day divided) — only with level monitoring where availablePyrimidine analogue; used with amphotericin in cryptococcal meningitis inductionBone-marrow suppression (monitor FBC), hepatotoxicity; resistance emerges if used alone — always combine
VoriconazoleLoading 6 mg/kg IV BD × 2 doses, then 4 mg/kg BD IV or 200 mg BD orallyAzole of choice for invasive aspergillosis; good CNS penetrationVisual disturbance (reversible), hepatotoxicity, phototoxicity (counsel sun protection), therapeutic drug monitoring advised; strong CYP interactions; avoid with rifampicin
Itraconazole200 mg BD (capsules with food or acidic drink for absorption)Azole for histoplasmosis, sporotrichosis, some aspergillosisAbsorption is erratic (check levels where available); negative inotropy — avoid in heart failure; CYP interactions
Caspofungin (echinocandin)Loading 70 mg IV, then 50 mg IV dailyInhibits β-glucan synthesis; candidaemia and salvage aspergillosisMild — infusion reactions, liver enzyme rise; poor CSF penetration
Terbinafine250 mg daily PO (weeks–months)Allylamine for dermatophyte and some invasive diseaseTaste disturbance, hepatotoxicity, rare marrow suppression — check LFTs on long courses

HIV-associated cryptococcal meningitis (standard approach)

Confirmed disease: induction with liposomal amphotericin B 3–4 mg/kg IV daily plus flucytosine 25 mg/kg QDS for 7 days, then consolidation fluconazole 400 mg daily for 8 weeks, then maintenance fluconazole 200 mg daily (continue until immune recovery on ART). Where amphotericin or flucytosine are unavailable, use fluconazole 1,200 mg daily — inferior but better than nothing. Manage raised intracranial pressure aggressively with repeated lumbar punctures/CSF drainage; start ART 2–6 weeks after antifungal therapy begins.

Monitoring and safety

  • Azoles — liver tests at baseline and during therapy; review every drug on the chart for CYP interactions (rifampicin lowers azole levels; azoles raise warfarin, phenytoin and statin levels).
  • Amphotericin B — daily creatinine, K+, Mg2+, FBC; hold or reduce when creatinine rises significantly.
  • Flucytosine — FBC and renal function; dose-adjust in renal impairment.
  • Voriconazole — trough levels where available, visual symptoms, LFTs, skin sun-protection advice.
  • Pregnancy — avoid azoles where possible in the first trimester; amphotericin B is the drug of choice for serious fungal disease in pregnancy.

Clinical scenario

A 34-year-old man with known HIV, not on antiretrovirals, presents after 3 weeks of progressive headache, fever and confusion. CD4 count is 28 cells/µL. Neck stiffness is present, and he has a few umbilicated papules on his face. Serum CrAg is positive. Lumbar puncture shows elevated opening pressure. Diagnosis: AIDS-associated cryptococcal meningitis. Manage: admit; begin liposomal amphotericin B 3–4 mg/kg IV daily plus flucytosine 25 mg/kg QDS for 7 days with pre-hydration and electrolyte monitoring; relieve the raised pressure with therapeutic lumbar punctures (remove 10–20 mL CSF, repeat daily while pressure is high); start fluconazole consolidation, then ART after 2–6 weeks. Oral thrush is not a prerequisite — this man needs antifungals, not another antibiotic course. If only fluconazole is available, use 1,200 mg daily and refer urgently for amphotericin.

Key points

References

  • SlideShare: Systemic mycoses (Library reference.)
  • Goodman & Gilman’s The Pharmacological Basis of Therapeutics (Library reference.)
  • Davidson’s Principles and Practice of Medicine (Library reference.)
  • WHO consolidated guidelines on HIV-associated cryptococcal disease (Library reference.)

Further reading

For deeper study, compare this lesson with current guidance and standard references from recognised medical and public-health organisations.

For education only. Apply current Uganda Clinical Guidelines, local protocols and specialist advice in clinical practice.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top